10Although there are reports of use of SGLT2i in patients withHNF1A-MODY, the use of SGLT2i is associated with increase in incidence of glycosuria and subsequently poses an increased risk of euglycemic diabetic ketoacidosis (DKA) and genital infection due to reduced endogenous insulin secretion characteristic of MODY patients.11, 12These considerations emphasize the need for careful patient selection, close monitoring, and further studies to evaluate the risk–benefit profile of oral hypoglycemic agents in MODY patients. Here, INS is linked to diabetic ketoacidosis.